Genethon and Ampersand Biomedicines Partner to Develop Precision Gene Therapy Vectors
Genethon and Ampersand Biomedicines join forces to engineer advanced AAV gene therapy vectors designed for greater tissue specificity, potentially enabling safer and more effective treatments for patients with rare genetic disorders.
Adeno-Associated Virus | 25/05/2026 | By News Bureau | 103
NIH-Funded Study Unveils Compact CRISPR System for Targeted In-Body Gene Editing
Researchers backed by the National Institutes of Health have developed an enhanced CRISPR enzyme that enables efficient gene editing and fits into viral delivery systems, advancing potential in-body therapies.
Adeno-associated Virus | 15/04/2026 | By News Bureau | 388
FDA Accepts IND for Affinia's AFTX-201 Gene Therapy in BAG3 Dilated Cardiomyopathy
Affinia Therapeutics receives FDA clearance to begin clinical testing of AFTX-201, a next-generation AAV gene therapy for BAG3-associated dilated cardiomyopathy, with Phase 1/2 UPBEAT trial set to begin in 2026.
Adeno-Associated Virus | 09/02/2026 | By News Bureau | 214
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy